{"nctId":"NCT01381900","briefTitle":"A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea","startDateStruct":{"date":"2011-08"},"conditions":["Diabetes Mellitus, Type 2"],"count":678,"armGroups":[{"label":"Canagliflozin 100mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin 100mg","Drug: Metformin","Drug: Sulphonylurea"]},{"label":"Canagliflozin 300mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin 300mg","Drug: Metformin","Drug: Sulphonylurea"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Metformin","Drug: Sulphonylurea"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Canagliflozin 100mg","otherNames":[]},{"name":"Canagliflozin 300mg","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Sulphonylurea","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with T2DM with inadequate glycemic control on metformin monotherapy or on metformin in combination with an SU at protocol-specified doses and having HbA1c \\>=7.0% and \\<=10.5% at Week -2 are eligible for enrollment in the study.\n\nExclusion Criteria:\n\n* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy\n* Has repeated (ie, 2 or more over a 1-week period) fasting plasma glucose (FPG) and/or fasting self-monitored blood glucose (SMBG) measurements \\>=270 mg/dL (15 mmol/L) during the pre-treatment phase, despite reinforcement of diet and exercise counseling\n* History of a severe hypoglycemic episode within 6 months before screening\n* History of or current illness considered to be clinically significant by the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18","description":"The table below shows the least-squares (LS) mean change in HbA1c from baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.096"},{"groupId":"OG001","value":"-0.97","spread":"0.095"},{"groupId":"OG002","value":"-1.06","spread":"0.095"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 18","description":"The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"0.237"},{"groupId":"OG001","value":"-1.44","spread":"0.236"},{"groupId":"OG002","value":"-1.83","spread":"0.235"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Body Weight From Baseline to Week 18","description":"The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 18 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.4"},{"groupId":"OG001","value":"-2.9","spread":"0.4"},{"groupId":"OG002","value":"-3.1","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <7% at Week 18","description":"The table below shows the percentage of patients with HbA1c \\<7% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"49.1","spread":null},{"groupId":"OG002","value":"52.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Glycosylated Hemoglobin (HbA1c) <6.5% at Week 18","description":"The table below shows the percentage of patients with HbA1c \\<6.5% at Week 18 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null},{"groupId":"OG001","value":"21.6","spread":null},{"groupId":"OG002","value":"25.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":226},"commonTop":["Hypoglycaemia","Upper respiratory tract infection"]}}}